ASTRAZENECA WKN: 886455 ISIN: GB0009895292 Kürzel: AZN Forum: Aktien Thema: Hauptdiskussion
130,92 USD
-1,30 %-1,73
23. Dec, 23:20:00 Uhr,
Nasdaq OTC
Kommentare 2.737
oxanabanana,
21.09.2021 8:29 Uhr
0
AstraZeneca to invest $360m in advanced manufacturing facility in Ireland
BankerBilo,
20.09.2021 18:38 Uhr
0
Nicht schlecht...
oxanabanana,
20.09.2021 14:59 Uhr
0
Zum Mond wird die nicht fliegen, bleibt aber im Vergleich zum schwachen Markt stabil
Aktenhai,
19.09.2021 20:43 Uhr
0
da wird ja eure Aktie am Montag zum Mond fliegen nach den Mega News
oxanabanana,
19.09.2021 20:19 Uhr
0
Und was war so lustig um kurz nach halb acht?
Beamta,
19.09.2021 7:36 Uhr
0
🤣
dynamic,
18.09.2021 22:11 Uhr
0
🤦🏻♂️
oxanabanana,
18.09.2021 19:01 Uhr
0
18 September 2021
Updated results from the CASPIAN Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
dynamic,
18.09.2021 15:54 Uhr
1
Hier gibt es fast nur noch posts von Oxana, schon seltsam.
Hast nix besseres zu tun ?
oxanabanana,
18.09.2021 15:31 Uhr
0
18 September 2021
Detailed positive results from the head-to-head DESTINY-Breast03 Phase III trial showed that Enhertu (trastuzumab deruxtecan), the AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), demonstrated superior progression-free survival (PFS) versus trastuzumab emtansine (T-DM1), a HER2-directed ADC currently approved to treat patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. Results were presented today in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2021.
oxanabanana,
18.09.2021 15:30 Uhr
0
18 September 2021
Detailed primary results from the positive Phase II DESTINY-Lung01 trial of Enhertu (trastuzumab deruxtecan), the AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), showed a robust and durable tumour response in previously treated patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC). Results presented during a late-breaking Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2021 and simultaneously published in The New England Journal of Medicine confirm Enhertu as the first HER2-directed therapy to show a strong tumour response in this patient population.
oxanabanana,
17.09.2021 21:02 Uhr
0
17 September 2021
Detailed results from the positive Phase II DESTINY-Gastric02 trial showed that Enhertu (trastuzumab deruxtecan), the AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), provided a clinically meaningful and durable tumour response in patients with HER2-positive metastatic and/or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with a trastuzumab-containing regimen. Results were presented during a late-breaking mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021.
oxanabanana,
17.09.2021 14:18 Uhr
0
17 September 2021
Results from the large, randomised COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi (durvalumab) improved progression-free survival (PFS) and objective response rate (ORR) compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).
Mehr zu diesem Wert
|
Thema | ||
---|---|---|---|
1 | ASTRAZENECA Hauptdiskussion | ||
2 | Short |
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | MicroStrategy | -7,14 % | |
2 | BTC/USD Hauptdiskussion | +0,35 % | |
3 | RHEINMETALL Hauptdiskussion | -0,99 % | |
4 | VALNEVA SE Hauptdiskussion | -5,53 % | |
5 | SALZGITTER Hauptdiskussion | -1,23 % | |
6 | Nikola Hauptforum | -2,54 % | |
7 | FRESENIUS SE Hauptdiskussion | -12,75 % | |
8 | LEONI Hauptdiskussion | ±0,00 % | |
9 | Lilium | -46,56 % | |
10 | SEALSQ Corp | +98,91 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | MicroStrategy | -7,14 % | |
2 | RHEINMETALL Hauptdiskussion | -0,99 % | |
3 | SALZGITTER Hauptdiskussion | -1,23 % | |
4 | VALNEVA SE Hauptdiskussion | -5,53 % | |
5 | Nikola Hauptforum | -2,54 % | |
6 | Lilium | -46,56 % | |
7 | SEALSQ Corp | +98,91 % | |
8 | NVIDIA Hauptdiskussion | +3,33 % | |
9 | DPCM Capital Hauptdiskussion | +21,72 % | |
10 | ATOS Hauptdiskussion | +10,00 % | Alle Diskussionen |